Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amy Burton

Pediatric Endocrinology Plano, TX Medical Doctor

NPI 1154544054 CMS profile 279795

5957 Dallas Pkwy Ste 100, Plano, TX 75093

Open in the dashboard

General payments

$130,380

1,138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Burton of Plano, TX is reported in the CMS Open Payments database as having received $130,380 across 1,138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,891 144
2024 General $45,660 158
2023 General $13,303 174
2022 General $9,106 212
2021 General $6,897 152
2020 General $6,764 142
2019 General $15,758 156

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Burton
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Amy Burton were reported at $32,891. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Amy Burton Pediatric Endocrinology median Middle half National median
2019 $15,758 $196 $68–$845 $163
2020 $6,764 $124 $37–$722 $114
2021 $6,897 $134 $35–$691 $132
2022 $9,106 $177 $47–$726 $149
2023 $13,303 $236 $75–$887 $160
2024 $45,660 $259 $91–$979 $164
2025 $32,891 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $70,012 69 payments
  2. Alexion Pharmaceuticals, Inc. $34,555 104 payments
  3. AbbVie, Inc. $9,831 142 payments
  4. Insulet Corporation $2,161 159 payments
  5. Pfizer Inc. $1,834 29 payments
  6. Novo Nordisk Inc $1,626 70 payments
  7. Tandem Diabetes Care, Inc. $1,141 14 payments
  8. Ascendis Pharma, Inc. $1,013 63 payments
  9. TOLMAR Pharmaceuticals, Inc. $884 92 payments
  10. Xeris Pharmaceuticals, Inc. $843 66 payments
  11. Other $6,480 330 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $101,415 58 payments
  2. Food and Beverage $19,799 1,015 payments
  3. Travel and Lodging $4,491 10 payments
  4. Consulting Fee $4,480 1 payment
  5. Education $195 54 payments
Products named General payments · program years 2019–2025
  1. TZIELD $70,012 69 payments
  2. LUPRON DEPOT $9,001 88 payments
  3. Strensiq Endocrinology $7,931 44 payments
  4. STRENSIQ Rare Disease $4,592 28 payments
  5. NGENLA $1,491 15 payments
  6. Omnipod Insulin Pump $1,251 92 payments
  7. FENSOLVI $1,178 85 payments
  8. SKYTROFA $1,013 63 payments
  9. Omnipod Insulin Pump $910 67 payments
  10. t-slim insulin pump $876 5 payments
  11. Other $10,104 547 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Pediatric Medicine: 38

Drug cost

$815

Median for Pediatric Medicine: $2,769

Branded share of claims

0%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocortisone Generic 11 $815

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
$40,269 — —
STRENSIQ
$675 — —
LUPRON DEPOT
$367 — —
FENSOLVI
$242 — —
Sogroya
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

1,138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record